Krystal's Vyjuvek becomes first topical gene therapy with FDA nod to treat rare skin disease
Fierce Pharma
MAY 19, 2023
Krystal's Vyjuvek becomes first topical gene therapy with FDA nod to treat rare skin disease zbecker Fri, 05/19/2023 - 16:25
Fierce Pharma
MAY 19, 2023
Krystal's Vyjuvek becomes first topical gene therapy with FDA nod to treat rare skin disease zbecker Fri, 05/19/2023 - 16:25
Pharmaceutical Technology
MAY 19, 2023
The US Food and Drug Administration (FDA) has granted approval to Bausch + Lomb and Novaliq’s Miebo (perfluorohexyloctane ophthalmic solution) to treat the signs and symptoms of dry eye disease (DED). Formerly known as NOV03, Miebo is a first-in-class eye drop designed for preventing the evaporation of excessive tears and restoring tear balance in evaporative DED patients.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
MAY 14, 2023
There is a huge opportunity for PBMs and health systems to use AI to help address the challenges surrounding the affordability and accessibility of medicines, from navigating formularies to resolving prior authorization. More automation in pharmacies and with ordering workflows is one piece of that puzzle.
Clarivate
MAY 18, 2023
As part of our on-going commitment to research integrity, we recently shared that we planned to investigate how we can provide greater transparency regarding which journals are covered in the Web of Science Core Collection. We thank our many community partners for their feedback and acknowledge the request for even more clarity around which journals are added or removed.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
Fierce Pharma
MAY 19, 2023
Intercept's NASH dreams may be dashed after FDA panel votes against Ocaliva's approval bid fkansteiner Fri, 05/19/2023 - 17:30
Pharmaceutical Technology
MAY 19, 2023
The US Food and Drug Administration (FDA) has approved AbbVie’s Rinvoq (upadacitinib) for patients with Crohn’s disease who do not respond to TNF blockers, a common immune suppressant treatment for the condition. Whilst there is a range of FDA-approved biologics for Crohn’s disease, Rinvoq is the first approved oral product for the moderate to severe type of the disease.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
PM360
MAY 15, 2023
Maya Angelou said, “If you’re going to live, leave a legacy. Make a mark on the world that can’t be erased.” For nine years, we have looked to recognize those people in healthcare and life sciences who are making a mark on our industry, on patients, on colleagues, on the world. These people represent our ELITE 100: the individuals and teams who throughout their careers are building legacies marked by helping people live better—and hopefully longer—lives.
Fierce Pharma
MAY 19, 2023
AbbVie, Genmab's lymphoma drug Epkinly snags FDA approval in heated blood cancer race aliu Fri, 05/19/2023 - 11:21
Pharmaceutical Technology
MAY 16, 2023
CHARM Therapeutics has received investment from NVIDIA’s venture investment arm, NVentures, for deep learning-enabled drug discovery research. Representing a major milestone for the company, the investment will enable CHARM to do further work on the research and development of new medicines for oncology. It will also allow the company to continue to fund its growing organisation while utilising the accelerated computing platform of NVIDIA.
MedCity News
MAY 16, 2023
Hippocratic AI emerged from stealth, as well as announced $50 million in seed funding through a round co-led by General Catalyst and Andreessen Horowitz. The Palo Alto-based startup bills itself as the first large language model designed specifically for healthcare.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
European Pharmaceutical Review
MAY 19, 2023
A Phase III trial has found that the novel combination antibiotic sulbactam-durlobactam prevents at least as many fatalities of hospital-acquired pneumonia as colistin, the best currently approved treatment. This finding alongside the other data from the trial led the US Food and Drug Administration (FDA)’s Antimicrobial Drugs Advisory Committee to recommend the FDA approve the combination antibiotic for often-fatal pneumonia strain carbapenem-resistant Acinetobacter baumannii–calcoaceticus co
Fierce Pharma
MAY 19, 2023
Bausch + Lomb bags FDA approval for dry eye disease treatment Miebo zbecker Fri, 05/19/2023 - 09:39
Pharmaceutical Technology
MAY 18, 2023
The European Medicines Agency (EMA) has published recommendations to increase communication and planning efforts in a bid stop the current medicine shortages becoming even worse. Within the 14-page document , published by an EMA special task force, are 10 recommendations of best practices that “marketing authorisation holders, wholesalers, distributors, and manufacturers can consider adopting to ensure continuity of medicinal product supply and reduce the impact of shortages”.
MedCity News
MAY 19, 2023
Included Health and DispatchHealth are partnering to combine Included’s virtual care services with DispatchHealth’s home care services. If an Included physician notices a patient requires in-person support, the physician will send DispatchHealth to the patient’s home.
Advertiser: ZoomInfo
In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.
European Pharmaceutical Review
MAY 19, 2023
Final draft guidance has been published for the first National Institute for Health and Care Excellence (NICE)-recommended treatment for symptomatic chronic heart failure with preserved or mildly reduced ejection fraction. The regulatory body’s decision means up to 150,000 patients would be eligible for AstraZeneca-made dapagliflozin (Forxiga).
Fierce Pharma
MAY 16, 2023
FTC seeks to block Amgen's $28B Horizon buy in 'broadly negative' move for biopharma M&A: report aliu Tue, 05/16/2023 - 09:41
Pharmaceutical Technology
MAY 19, 2023
Myeloid Therapeutics has raised $73m to support the continued clinical development of its lead cell therapy programme, MT-101, in Phase I/II trials for T cell lymphoma. Led by Hatteras Investment Partners, the financing round has seen participation from existing investors, including 8VC, Alexandria Venture Investments and Newpath Partners, along with new investors Moore Strategic Ventures and ARCH Venture Partners.
MedCity News
MAY 14, 2023
We must engage, train and support more physicians as investigators to enable the opportunity for their patients to have access to clinical trials. As an industry, we should be adding anywhere from 10% to 20% new investigators every year to meet the patient access needs for clinical trials.
Advertiser: ZoomInfo
Shifting to an account-based marketing (ABM) strategy can be both exciting and challenging. Well-implemented ABM motions build engagement with high-value accounts and drive impactful campaigns that resonate with your audience. But where do you begin, and how do you progress from crawling to running? Watch now as Demand Gen experts delve into the essentials of each stage of the ABM process.
Clarivate
MAY 18, 2023
Marko Damjanovic, Head of Corporate Sustainability at Clarivate, reviews our 2022 ESG milestones and highlights our 2023 goals for advancing our strategic commitments to the United Nations SDGs – all by accelerating our actions and by helping our customers achieve their goals. At Clarivate we put sustainability at the heart of our business goals and we want environment, social and governance issues to be the core of our global culture, serving as guiding principles for every decision we make.
Fierce Pharma
MAY 17, 2023
Regulatory tracker: Another China-made PD-1 starts FDA journey as Elevar, Hengrui target big cancer type aliu Wed, 05/17/2023 - 09:41
Pharmaceutical Technology
MAY 19, 2023
Multiple sclerosis (MS) is a primary autoimmune disease in which inflammation is a core contributor to the degeneration of the central nervous system (CNS), leading to neurological disability and affecting sensory, visual, motor, and autonomic systems. While MS is not a terminal diagnosis, the effect of the disease on the CNS can significantly impact patients’ independence and disturb their daily lives.
MedCity News
MAY 17, 2023
Lucem Health recently closed a $7.7 million Series A funding round. The startup’s platform takes in the data required to fuel AI algorithms that give clinicians insights to improve patient care.
Advertiser: ZoomInfo
One of the biggest challenges for any B2B marketer is understanding your prospects’ next move — who is most likely to buy and when. Without these insights, marketing campaigns can feel more like guesswork, with high investment and little return. We’re here to tell you there’s a better way. By tracking buyers’ digital footprints and online activity, such as website visits, product reviews, and spikes in content consumption, you can engage prospects with a message that really resonates.
Pharmatutor
MAY 16, 2023
Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) : Making Quality Medicines Affordable and Accessible in India admin Tue, 05/16/2023 - 15:25 About Author Ramraj Choudhary M.Pharma, (Pharmaceutics) Dr. H.S Gour University, Sagar MP Current Position : Sr.
Fierce Pharma
MAY 16, 2023
AstraZeneca follows AbbVie, Teva in surprising departure from lobbying group PhRMA zbecker Tue, 05/16/2023 - 11:06
Pharmaceutical Technology
MAY 17, 2023
Multiple Myeloma Research Foundation’s (MMRF) venture philanthropy subsidiary Myeloma Investment Fund (MIF) has made an undisclosed investment in Nectin Therapeutics to assess the potential of NTX1088 to treat multiple myeloma. Along with the MIF’s investment, Nectin has so far secured more than $33m from aMoon, Peregrine Ventures, Israel Biotech Fund, Cancer Focus Fund and Integra.
MedCity News
MAY 16, 2023
In a wide-ranging interview, Sanford Health’s president of virtual care explained how virtual care may be well suited to rural populations.
Advertiser: ZoomInfo
In this eBook, we’ll run through real-world examples that show how RevOps teams can benefit from modern solutions for the access, management, and activation of their GTM data. Whether you need to improve lead response times, boost adoption of core tools, improve lead qualification, or target and automate your GTM motions, you’ll find examples of how revenue teams are solving some of the toughest problems in modern business.
PharmaTech
MAY 15, 2023
Forge will provide adeno-associated virus (AAV) process development, toxicology, cGMP manufacturing, and analytical services to Life Bio, which will occur at Forge’s gene therapy facility in Columbus, Ohio called the Hearth.
Fierce Pharma
MAY 18, 2023
Teva's new CEO Francis lays out his 'pivot to growth' strategy kdunleavy Thu, 05/18/2023 - 11:24
Pharmaceutical Technology
MAY 16, 2023
The US Food and Drug Administration (FDA) has approved expanded labelling for Cumberland Pharmaceuticals’ Caldolor therapy to include use in infants. Caldolar is an intravenously provided formulation of ibuprofen which may now be administered to treat pain and fever in patients from three months to six months of age. The newly approved label features information about the product’s indications and usage, suitable patient groups, clinical trial results, potential side effects and patient safety
MedCity News
MAY 15, 2023
By selling partial royalties to approved hemophilia gene therapy Hemgenix, uniQure gains immediate cash to support its pipeline, including a Huntington’s disease gene therapy already in the clinic. The royalty deal extends uniQure’s cash runway into 2026.
Advertiser: ZoomInfo
Consolidating your tech stack is an effective cost-saving measure that drives GTM efficiency and adds value to your enterprise. With a cohesive, integrated tech stack, your revenue teams can deliver an excellent customer experience that sets you up to win faster than your competitors.
Let's personalize your content